Value-Added Medicines

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

Reformulation specialist Lipella has an eye on numerous milestones for its proposed oral rinse liposomal formulation of tacrolimus, including the submission of a Phase IIb clinical trial investigational new drug application.

Adial Pharmaceuticals’ CEO Cary Claiborne discussed with Generics Bulletin how repurposing antinausea drug ondansetron and genetically targeting patients with specific biomarkers can address the unmet need in the current treatment of addiction.

CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.

In its presentation at this year’s J.P. Morgan Healthcare Conference, Hikma highlighted its efforts in all three of its businesses, with optimism across the board.

Recently-appointed president of Medicines for Europe Stephan Eder speaks to Generics Bulletin about the off-patent association’s priorities to secure a sustainable operating environment for the generics, biosimilars and value-added medicines sector in Europe.

In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.

In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.